Lifevantage Corporation (LFVN)

From the record

Lifevantage Corporation's filings since 2017 show 2 warning events: an auditor change (8-K item 4.01, 2 times, the latest 2023-04-17) (its current reports).

From the record

Lifevantage Corporation's 10 filed years say what it did: revenue went from $199 million in fiscal 2017 to $183 million in fiscal 2026, down 1% a year; it rose in 5 of 9 years; the deepest fall was 22% from fiscal 2020 to fiscal 2026; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-06-30, Lifevantage Corporation's diluted share count grew about 0.4% a year, and dividends and buybacks returned about 67% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 4 sales and 8 purchases of their own stock on the open market in the year to 2026-11-09, buying about $196 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-06-30, Lifevantage Corporation earned about 15 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 228 cents per dollar of everything the company owns. Leverage: it owed about 46 cents per dollar of assets, and net share issuance: its share count shrank 2.2% over the year (the filed statements).

From the record

Lifevantage Corporation's standing among 315 graded names in its industry family: revenue of $183 million in fiscal 2026 ranks in the top 30% by size; a net margin of 2.8% ranks in the top 22%; revenue growth of -5.1% a year over the last 3 filed years ranks in the bottom 30% (its annual reports).

From the record

Lifevantage Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Moorehead, Terrence (President and CEO, as filed), filing under that title since 2026-08-10, 3 months (bottom 3% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 4.7 years (bottom 31%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Lifevantage Corporation's room to grow, from the newest filed statements (fiscal 2026): cash of $15 million against no long-term debt tagged leaves 24% of its assets as net cash, bottom 45% of its family; cash from operations less capital spending is 3.7% of revenue (top 27%); a gross margin of 77.6% (top 38%); research spending of 0.5% of revenue (bottom 2%) (its annual report).

From the record

Lifevantage Corporation's growth drivers, from the filed years to fiscal 2026: revenue grew -5.1% a year over the last three filed years against -1% over all 10, slowing (bottom 45% of its family); the newest year grew -20.1% (bottom 27%); research spending grew 18.6% a year (top 26%); capital spending grew 5.2% a year (top 34%) (its annual reports). Lifevantage Corporation reported 7 product lines in fiscal 2026: Protandim at $82 million (45%), True Science Product Line at $38 million (21%), Life Vantage Product Line at $32 million (18%), and 4 more; 0 of 6 grew against the year before (its annual report).

From the record

Lifevantage Corporation's newest year against its own record: revenue of $183 million in fiscal 2026 came in 22.8% below the $236 million its prior three years' pace pointed to (bottom 31% of its family); net income of $5 million against a prior three-year average of $5 million (bottom 41%); a net margin of 2.8% against 2.3% before (bottom 36%) (its annual reports).